組織プラスミノーゲンアクチベータ静注療法後に口舌血管性浮腫を来したオルメサルタン内服中の心原性脳塞栓症患者の1例

DOI Web Site Web Site 参考文献13件

書誌事項

タイトル別名
  • Orolingual Angioedema after Recombinant Tissue Plasminogen Activator Treatment in Acute Cardiogenic Cerebral Embolism Patient Using Olmesartan: A Case Report
  • ソシキ プラスミノーゲンアクチベータ ジョウチュウ リョウホウ ゴ ニ コウゼツ ケッカンセイ フシュ オ キタシタ オルメサルタン ナイフク チュウ ノ シン ゲンセイ ノウ ソクセンショウ カンジャ ノ 1レイ

この論文をさがす

抄録

<p>Recombinant tissue plasminogen activator (rt-PA), which is used to treat acute cerebral infarction, may cause angioedema immediately after administration particularly in patients who are taking angiotensin-converting enzyme (ACE) inhibitors. On the other hand, unlike ACE inhibitors, angiotensin II receptor blockers (ARBs) do not act directly on bradykinin, and are therefore considered an alternative to ACE inhibitors in patients with bradykinin-related side effects. We report a case of orolingual angioedema in an 82-year-old male patient who is taking ARB, which occurred after rt-PA administration for acute cerebral infarction. The patient, who has been on medications for hypertension including ARB (olmesartan 40 mg/day) and for hyperuricemia, was transported to our hospital with the chief complaint of right conjugate deviation of the eyes and left hemiplegia. Head magnetic resonance imaging revealed cerebral infarction in the right mesencephalic artery area including the insular cortex. He was diagnosed with cardiogenic cerebral embolism, and rt-PA administration was started 4 h after onset. The patient developed eyelid edema 2.5 h after the start of administration, and orolingual angioedema and breathing difficulty 15.5 h after. The patient was treated with methylprednisolone, d-chlorpheniramine maleate, and famotidine, and the symptoms improved gradually in 1.5 h. We should pay attention to the occurrence of orolingual angioedema not only at the beginning of rt-PA administration but also for a long time thereafter when it is used in patients taking ARBs.</p>

収録刊行物

  • 薬学雑誌

    薬学雑誌 142 (1), 85-89, 2022-01-01

    公益社団法人 日本薬学会

参考文献 (13)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ